Aminoglycosides Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.11 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Aminoglycosides Market Analysis
The aminoglycosides market is expected to record a CAGR of 4.11% over the forecast period (2022-2027).
The COVID-19 outbreak significantly impacted the healthcare sector. As per the article published in 2021 under the title 'Aminoglycosides and their potential as SARS-CoV-2 antivirals', as the defense mechanism implemented by aminoglycosides, it was anticipated to be worth researching as SARS-CoV-2 antivirals. Moreover, murine hepatitis virus (MHV) inhibition by the aminoglycosides hygromycin B (hygB) and neomycin has been demonstrated in vitro. Furthermore, as per the article published in 2021 under the title 'Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents', Aminoglycosides were likely to be used as a base to create powerful COVID-19 medicinal compounds. Hence, as per the factors mentioned above, COVID-19 had a significant impact on the loratadine market.
The major factors driving the market growth include the growing instances of animal disease outbreaks, leading to the high utilization of antibiotics, a rise in the aging population, and the increasing prevalence of bacterial infectious diseases. For instance, as per the article published in 2022 under the title 'Correlation between antibiotic consumption and the occurrence of multidrug-resistant organisms in a Malaysian tertiary hospital: a 3-year observational study', the study showed that broad-spectrum antibiotics and antibiotics against multidrug-resistant organisms (MRO) consumption increased significantly throughout in the studied region. In humans and animals, the usage of aminoglycosides in the treatment of different bacterial infections is increasing due to the presence of characteristics such as bactericidal activity against staphylococci and certain mycobacteria, which is expected to influence market growth.
Moreover, this class of antibiotics is found to be effective even when bacterial inoculum is large, and it is frequently used as a second line of defense against basic infection resistant to basic antibacterial. The increasing burden of tuberculosis is also expected to drive the demand for aminoglycosides, especially in low-income countries where the incidence is alarmingly high and there is a need for aminoglycosides. For instance, as per the World Health Organization (WHO) 2021 update, a total of 1.5 million people died from tuberculosis in 2020 (including 214,000 people with HIV). Globally, COVID-19 (after HIV/AIDS) is the second most lethal infectious disease, while tuberculosis is the 13th most common cause of death.
As per the facts mentioned above aminoglycosides, market is expected to grow over the forecast period. However, a reduction in the prescription rate of aminoglycoside antibiotics due to side effects associated with the usage of these drugs which include severe ototoxicity, nephrotoxicity, and neuromuscular blockade is expected to restrain the market growth.
Aminoglycosides Market Trends
This section covers the major market trends shaping the Aminoglycosides Market according to our research experts:
The Gentamicin Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Gentamicin is used in the treatment of serious infections that are caused by bacteria, such as infections of the blood, lungs, bones, joints, skin, and urinary tract and meningitis (infection of the membranes that surround the brain and spinal cord). Gentamicin is the agent of choice for major bacterial infections.
Increased research and development in the field of Gentamycin related topics boost the market growth. For instance as per the article published in 2022 under the title 'Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review', in both adults and children older than one month, including critically ill patients, a conventional gentamicin beginning dose of 7 mg/kg based on total body weight (or on ABW in obese patients) appears to be the most effective method for increasing the probability of target attainment (PTA) after the initial administration.
In veterinary medicine, drugs such as Gentamicin and Amikacin find maximum usage. Gentamicin is indicated in sepsis, acute/chronic renal disease, diabetes, perinatal complications, labor or neonatal complications, and UTI/pyelonephritis.
According to a research article published in 2020 under the title 'Epidemiology of urological infections: a global burden', globally, urinary tract infections were among the most frequent infections in clinical practice. The high burden of urinary tract infections is expected to increase the use of Gentamicin over the forecast period. Moreover, gentamicin forms the first line of treatment for many diseases. The usage of Gentamicin is particularly high in developing regions where it is a cost-effective and efficacious drug for many infectious diseases.
Thus, the demand for Gentamicin is consistently growing for different bacterial-related diseases, with several players using it in combinations. Hence, the aforementioned factors are expected to drive the market over the forecast period.
North America is Expected to Hold a Major Market Share Over the Forecast Period
The major factors driving the aminoglycoside market growth in North America include the increasing incidence of bacterial infections, growing demand for early-phase diagnosis and treatment of infectious diseases, and support from the government in the prevention of infection.
According to a research study published in August 2020 titled 'Studies highlight the dynamic impact of COVID-19 on antibiotic use', more than 1,700 hospitalized COVID-19 patients were treated at 38 Michigan hospitals in the United States from March 13, 2020, to June 18, 2020, more than half received early antibiotic therapy, with antibiotic use as high as 84% in some hospitals, which showed a positive impact on the market growth. Increased healthcare expenditure in the studied region boosts market growth. For instance, according to the 2021 report from WHO, by 2022, USD 13 billion is likely to be needed annually for TB prevention, diagnosis, treatment, and care to achieve the global target agreed upon at the UN high-level meeting on TB in 2018. Increasing funding and government initiatives are expected to drive the demand for aminoglycosides in the prevention of infectious diseases. For instance, one of the health objectives of the United Nations Sustainable Development Goals is to end the tuberculosis (TB) epidemic by 2030.
As per the factors mentioned above, the North America market is expected to grow over the forecast period.
Aminoglycosides Industry Overview
The aminoglycosides market is moderately fragmented and competitive. The market studied is composed of a large number of players and includes both small and large pharmaceutical manufacturers. Additionally, the increasing antibiotic resistance has prompted many early-stage biotechnology enterprises to enter this market. The expiry of patent exclusivity has led to large-scale generic manufacturing of aminoglycosides, particularly in the developing region of Asia-Pacific. The key market players include Cipla Limited, Pfizer Inc., AbbVie Inc. (Allergan PLC), Teva Pharmaceutical Industries Ltd, and Zoetis Inc., among others.
Aminoglycosides Market Leaders
-
Pfizer Inc.
-
AbbVie Inc (Allergan Plc)
-
Teva Pharmaceutical Industries Ltd
-
Zoetis Inc
-
Cipla Limited
*Disclaimer: Major Players sorted in no particular order
Aminoglycosides Market News
- In March 2022, Padagis received the United States Food and Drug Administration approval for its AB-rated generic version of Tobradex Ophthalmic Suspension. It contains active ingredients such as tobramycin and dexamethasone. Tobradex Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
- In May 2022, Leiden University Medical Center sponsored a clinical trial under the title 'Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention (INSTILMENT)', in the study the researchers are investigating the effectiveness of intravesical aminoglycoside instillations (IAI) that have been shown to reduce recurrence rate, without a short-term decline in kidney function or hearing.
Aminoglycosides Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Instances of Animal Disease Outbreaks Leading to High Utilization of Antibiotics
4.2.2 Increase in Aging Population
4.2.3 Increasing Prevalence of Bacterial Infectious Diseases
4.3 Market Restraints
4.3.1 Adverse and Toxic Reactions Associated with Aminoglycosides
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Product
5.1.1 Neomycin
5.1.2 Tobramycin
5.1.3 Gentamicin
5.1.4 Amikacin
5.1.5 Paromomycin
5.1.6 Streptomycin
5.1.7 Kanamycin
5.1.8 Other Aminoglycosides
5.2 By Route of Administration
5.2.1 Parenteral
5.2.2 Intra-mammary
5.2.3 Topical
5.2.4 Oral
5.3 By Application
5.3.1 Veterinary
5.3.2 Skin Infection
5.3.3 Respiratory Diseases
5.3.4 UTI and Pelvic Diseases
5.3.5 Other Diseases
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Cipla Limited
6.1.2 Pfizer Inc.
6.1.3 AbbVie Inc. (Allergan PLC)
6.1.4 Novartis AG
6.1.5 Johnson & Johnson
6.1.6 Bristol Myers Squibb Company
6.1.7 Vega Pharma Ltd
6.1.8 Xian Wison Biological Technology Co. Ltd
6.1.9 Yi Chang Veterinary Medicine Factory
6.1.10 Insmed Incorporated
6.1.11 Teva Pharmaceutical Industries Ltd
6.1.12 Achaogen Inc.
6.1.13 Sun Pharmaceutical Industries Limited
6.1.14 Chiesi Farmaceutici
6.1.15 Zoetis Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Aminoglycosides Industry Segmentation
As per the scope of this report, aminoglycosides are highly potent antibiotics with several properties for the treatment of life-threatening infections. Aminoglycosides have concentration-dependent bactericidal activity by binding to the 30S ribosome that inhibits bacterial protein synthesis. The aminoglycosides market is segmented by product (Neomycin, Tobramycin, Gentamycin, Streptomycin, Kanamycin, Paromomycin, Amikacin, Verdamicin, Astromicin, and Hygromycin B), route of administration (parenteral, intra-mammary, topical, and oral), application (veterinary, skin infection, respiratory diseases, UTI and pelvic diseases, and other diseases), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product | |
| Neomycin | |
| Tobramycin | |
| Gentamicin | |
| Amikacin | |
| Paromomycin | |
| Streptomycin | |
| Kanamycin | |
| Other Aminoglycosides |
| By Route of Administration | |
| Parenteral | |
| Intra-mammary | |
| Topical | |
| Oral |
| By Application | |
| Veterinary | |
| Skin Infection | |
| Respiratory Diseases | |
| UTI and Pelvic Diseases | |
| Other Diseases |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Aminoglycosides Market Research FAQs
What is the current Global Aminoglycosides Market size?
The Global Aminoglycosides Market is projected to register a CAGR of 4.11% during the forecast period (2024-2029)
Who are the key players in Global Aminoglycosides Market?
Pfizer Inc., AbbVie Inc (Allergan Plc), Teva Pharmaceutical Industries Ltd, Zoetis Inc and Cipla Limited are the major companies operating in the Global Aminoglycosides Market.
Which is the fastest growing region in Global Aminoglycosides Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Aminoglycosides Market?
In 2024, the North America accounts for the largest market share in Global Aminoglycosides Market.
What years does this Global Aminoglycosides Market cover?
The report covers the Global Aminoglycosides Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Aminoglycosides Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Aminoglycosides Industry Report
Statistics for the 2024 Aminoglycosides market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Aminoglycosides analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
